Prospective Randomized Trial of Esomeprazole versus Lansoprazole and Omeprazole Based Triple Therapy for H. Pylori Eradication in an Iranian Population

Background: Although triple therapy with one proton pump inhibitor (PPI) and two antibiotics for one week has been introduced as the treatment of choice, quadruple therapy in Iran is the standard treatment due to the organism’s high resistance is related to Helicobacter pylori (H. pylori) organism. Objective: Comparison of three different PPIs; esomeprazole, lansoprazole and omeprazole with a longer duration (10 days) for eradication of H. pylori in the Iranian population. Methods and Materials: Two-hundred ninety-four patients with endoscopic evidence of peptic ulcer, non-ulcer dyspepsia, gastritis or acid reflux and confirmed H. pylori, either by histology or a positive urea test were randomly divided into three groups; namely, group I (98 patients) received omeprazole, clarithromycin and amoxicillin (OCA); group II (97 patients) received lansoprazole (LCA) and group III (98 patients) received esomeprazole (NCA) instead of omeprazole. Response to treatment was defined as eradication of H. pylori confirmed by negative C14 urea breath test 40 days after treatment course completion.